Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Why Grifols Stock Is on Investors’ Radar
Grifols (BME:GRF) has drawn fresh attention after a period where returns have diverged across timeframes, with gains over the past year contrasting with weaker moves in the month and past 3 months.
At a last close of €8.94, the stock reflects recent short term pressure. At the same time, longer term figures and the current earnings profile, including €7,438.0m in revenue and €415.0m in net income, keep the company in focus for investors assessing risk and potential reward.
See our latest analysis for Grifols.
Recent trading has been under pressure, with a 1-day share price decline of 2.36% to €8.94 and a 90-day share price decline of 17.76%, while the 1-year total shareholder return of 11% highlights how sentiment has shifted over different time horizons.
If you are weighing Grifols against other opportunities in the sector, it can be useful to see how the market is pricing potential in healthcare focused AI stocks through the 124 healthcare AI stocks
With Grifols trading at €8.94 despite recent revenue of €7,438.0m and net income of €415.0m, plus a sizable discount to analyst targets, you have to ask: is this a mispriced opportunity, or is future growth already fully reflected?
Most Popular Narrative: 40.7% Undervalued
Grifols’ most followed narrative points to a fair value of €15.08 per share versus the last close of €8.94, framing a sizeable valuation gap that hinges on future earnings power and cash flow quality.
Disciplined cost management, deleveraging efforts, and normalization of business operations are strengthening Grifols’ balance sheet and enabling higher free cash flow generation, supporting reinvestment and the resumption of shareholder returns, positively impacting net margins and overall earnings quality.
Analysts are incorporating expectations of faster profit growth than revenue, a clear step up in margins, and a richer earnings multiple by 2028. This raises the question of how those moving parts line up to support a higher fair value than today’s price, and which assumptions carry the most weight in that narrative.
Result: Fair Value of €15.08 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, you still need to factor in risks like high debt and potential pricing pressure in key markets, which could challenge the undervaluation story.
Find out about the key risks to this Grifols narrative.
Next Steps
With mixed signals on value, risk, and reward, the key issue is how you weigh them for your own portfolio. Look through the details, stress test your assumptions, and see how they stack up against the 4 key rewards and 1 important warning sign
Looking for more investment ideas?
Once you have a view on Grifols, do not stop there. Broader ideas can help you balance risk, spot fresh opportunities, and avoid overloading on a single story.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GRF.MC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com